XTX Topco’s Benitec Biopharma BNTC Stock Holding History

XTX Topco’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,845	Closed	-$127K	–	2597
2025 Q2	$127K	Buy	+10,845	New	+$152K	0.01%	1829

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

XTX Topco's BNTC Position: Q3 2025 in Review

XTX Topco sold out of Benitec Biopharma (BNTC) in Q3 2025, closing a stake of 10,845 shares — an estimated $127K sold.

XTX Topco first reported a position in BNTC in Q2 2025 and held it in 1 quarter. The position peaked at $127K in Q2 2025. 56 funds tracked by Wall St. Rank hold BNTC as of Q3 2025.

XTX Topco reported no remaining Benitec Biopharma position as of Q3 2025 after selling out during the quarter.
XTX Topco sold 10,845 Benitec Biopharma shares in Q3 2025, an estimated $127K.
XTX Topco first reported a position in Benitec Biopharma in Q2 2025 and held it in 1 quarter.
XTX Topco's Benitec Biopharma position peaked at $127K in Q2 2025.
56 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.